Q4 2025 Mink Therapeutics Inc Earnings Call Transcript
Key Points
- MiNK Therapeutics Inc (INKT) has advanced its allogeneic invariant natural killer T cell platform into Phase 2 clinical trials for solid tumor cancers and autoimmune inflammatory conditions, demonstrating durable survival and complete remission in heavily pretreated cancers.
- The company has secured external funding for trials in graft versus host disease and gastric cancer, with results expected to be presented at a major conference in the first half of the year.
- MiNK Therapeutics Inc (INKT) is executing its programs with capital efficiency, combining disciplined internal execution with non-dilutive funding through government and institutional partnerships.
- The company has strengthened its financial position, increasing cash to $13.4 million while reducing operating costs by nearly 40% over the year.
- MiNK Therapeutics Inc (INKT) is expanding its pipeline with non-dilutive funding, advancing its PRIME TCR NKT program and CAR iNKT program targeting stromal resistance.
- The company faces risks and uncertainties related to clinical development, regulatory and commercial plans, and timelines for data releases and partnership opportunities.
- MiNK Therapeutics Inc (INKT) has not yet publicly posted its hypoxemic pneumonia program, leaving some details about the trial design and patient population unclear.
- The company has not formally announced any strategic collaborations or clinical trials with the IL-15 superagonist, despite receiving inquiries about it.
- There are no specific near-term catalysts for the MiNK-215 CAR iNKT program, with announcements expected in the next three to five months.
- The company reported a net loss of $12.5 million for the full year 2025, reflecting continued investment in advancing its clinical programs.
Good morning and welcome to MiNK Therapeutics fourth quarter and year end 2025 financial results conference call. (Operator Instructions) As a reminder, this event is being recorded. If anyone has any objections, you may disconnect at this time.
I would now like to turn the conference over to Stefanie Perna-Nacar, Chief Communications Officer. Please go ahead.
Thank you, operator, and thank you all for joining us today. Today's call is being webcast and will be available on our website for replay. I'd like to remind you that this call will include forward-looking statements, including notes related to our clinical development, regulatory and commercial plans, time lines for data releases and partnership opportunities.
These statements are subject to risks and uncertainties. Please refer to our SEC filings available on our website for a detailed description of these risks. Joining me today are Dr. Jennifer Buell, President and Chief Executive Officer
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
